IRIS
MORGILLO, Floriana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.690
NA - Nord America 4.394
AS - Asia 4.088
SA - Sud America 649
AF - Africa 51
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
Totale 20.889
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 7.545
US - Stati Uniti d'America 4.305
SG - Singapore 1.469
IE - Irlanda 1.192
CN - Cina 937
IT - Italia 835
HK - Hong Kong 725
BR - Brasile 568
DE - Germania 456
GB - Regno Unito 430
UA - Ucraina 402
FR - Francia 276
KR - Corea 253
VN - Vietnam 209
FI - Finlandia 154
SE - Svezia 142
TR - Turchia 131
IN - India 117
GR - Grecia 98
JP - Giappone 85
CA - Canada 51
AT - Austria 35
AR - Argentina 34
PK - Pakistan 34
BD - Bangladesh 26
BE - Belgio 24
MX - Messico 24
NL - Olanda 24
ID - Indonesia 19
IQ - Iraq 14
ZA - Sudafrica 13
ES - Italia 12
PL - Polonia 11
CO - Colombia 10
CZ - Repubblica Ceca 10
EC - Ecuador 10
CL - Cile 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 7
HU - Ungheria 7
IR - Iran 7
TW - Taiwan 7
UZ - Uzbekistan 7
EG - Egitto 6
MA - Marocco 6
NZ - Nuova Zelanda 6
PY - Paraguay 6
TN - Tunisia 6
AU - Australia 5
AZ - Azerbaigian 5
EU - Europa 5
IL - Israele 5
KE - Kenya 5
SA - Arabia Saudita 5
LT - Lituania 4
MK - Macedonia 4
PE - Perù 4
PH - Filippine 4
VE - Venezuela 4
AL - Albania 3
AO - Angola 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
JO - Giordania 3
KZ - Kazakistan 3
OM - Oman 3
RO - Romania 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
CG - Congo 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
ML - Mali 1
NO - Norvegia 1
PS - Palestinian Territory 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
Totale 20.888
Salva come PNG Salva come JPEG
Città #
Moscow 2.604
Dublin 1.184
Hong Kong 724
Chandler 662
Jacksonville 631
Santa Clara 621
Singapore 612
Seoul 231
Princeton 164
Beijing 162
Bremen 162
Naples 158
New York 137
Ashburn 135
Medford 129
Ann Arbor 128
Hefei 125
Roxbury 125
Caserta 119
Dallas 119
Munich 106
Wilmington 87
Bengaluru 86
Ho Chi Minh City 81
The Dalles 79
Boardman 59
São Paulo 58
Nanjing 55
San Mateo 46
Woodbridge 45
Cambridge 44
Los Angeles 41
Turku 38
Des Moines 37
Hanoi 36
Napoli 34
Nuremberg 29
Elora 28
Brussels 24
Dong Ket 24
Houston 24
Jinan 22
Rio de Janeiro 21
Rome 19
Mountain View 18
Vienna 18
Tianjin 17
Nanchang 16
Amsterdam 15
Brasília 15
Helsinki 15
Aiello Del Sabato 14
Brooklyn 14
Milan 14
Council Bluffs 13
Düsseldorf 13
Afragola 12
Belo Horizonte 12
Istanbul 12
Norwalk 12
Shanghai 12
Aversa 11
Curitiba 11
Ercolano 11
Haiphong 11
Zhengzhou 11
Guarulhos 10
Lappeenranta 10
London 10
Auburn Hills 9
Boston 9
Brno 9
Falkenstein 9
Hangzhou 9
Bahawalpur 8
Da Nang 8
Guangzhou 8
Jakarta 8
Ninh Bình 8
Shenyang 8
Cava Dei Tirreni 7
Columbus 7
Goiânia 7
Lanzhou 7
Rawalpindi 7
Ribeirão Preto 7
San Francisco 7
Sorocaba 7
Taiyuan 7
Tokyo 7
Toronto 7
Venice 7
Warsaw 7
Campinas 6
Cape Town 6
Changchun 6
Changsha 6
Chengdu 6
Dhaka 6
Giugliano in Campania 6
Totale 10.608
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 220
ONCOLOGIA MEDICA 196
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 190
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 185
AXL is an oncotarget in human colorectal cancer 171
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 171
Adequacy of Cytologic Samples by Ultrasound-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology of Peripheral Pulmonary Nodules for Morphologic Diagnosis and Molecular Evaluations: Comparison With Computed Tomography-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology 169
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 169
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 166
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 163
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 163
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 162
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 159
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 158
Chronic inflammation and oxidative stress in human carcinogenesis 158
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 157
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 156
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 155
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 155
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 152
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 150
Immunotherapy for head and neck cancer: Present and future 148
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 147
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 146
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 146
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 145
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 144
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 143
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 143
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 143
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 141
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 141
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 137
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 136
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 136
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 135
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 134
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 133
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 133
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 132
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 132
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold! 132
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 131
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 130
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 130
Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication(dagger) 128
Farmacogenomica e cancro colorettale 126
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 126
TRASTUZUMAB RESISTANCE IN BREAST CANCER 125
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 123
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 123
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 123
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 123
Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up 122
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 121
The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. 121
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 121
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 120
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival 120
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 119
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 119
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 118
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. 117
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 116
Targeting EGFR in Pancreatic Cancer Treatment. 116
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 116
PercuTwist tracheostomy in an intubated patient with tracheal stent 116
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 115
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 115
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 115
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 115
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 114
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 114
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 113
PET-TC BODY CON FDG IN ONCOLOGIA 113
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 113
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 112
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 112
Trimodality treatment in early-stage malignant pleural mesothelioma. Preliminary results of a multicenter phase II trial 112
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 112
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 111
AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma 111
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 110
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 110
Preoperative chemo-radiotherapy for carcinoma of the esophagus 109
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 109
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 109
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 108
Pimasertib hydrochloride 108
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib 107
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 106
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 105
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 105
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 105
Metformin in lung cancer: rationale for a combination therapy 104
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 104
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 104
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 104
It is finally time for adjuvant therapy in melanoma 104
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 103
Totale 13.113
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.707
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.707
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021593 0 0 0 0 0 12 137 99 23 133 126 63
2021/20221.185 56 17 24 28 374 17 45 45 49 101 107 322
2022/20232.502 253 65 39 245 311 203 11 146 1.115 19 49 46
2023/2024935 82 34 43 55 291 132 18 26 16 18 74 146
2024/20253.049 33 62 30 77 453 402 397 261 438 412 260 224
2025/202610.566 516 605 653 619 1.053 7.120 0 0 0 0 0 0
Totale 21.360